ANI Pharma CEO sells $383K in stock at $71

ANI Pharmaceuticals’ CEO sold 5,400 ANIP shares under a pre-arranged Rule 10b5-1 trading plan, retaining a substantial direct stake.

Available on EDGAR 09/16/2026 - 04:21 PM EDT Accepted by SEC EDGAR 09/16/2026 - 04:20 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

ANI PHARMACEUTICALS INC (ANIP) reports that President and CEO Nikhil Lalwani sold 5,400 shares of common stock on September 15, 2026 at $71.00 per share, for about $383,400 in total proceeds. After this transaction, he directly holds 339,089 shares. The sale was effected under a Rule 10b5-1 trading plan adopted on May 26, 2026.

Insider Trade Summary 10b5-1

Net Seller: 5,400 shares

Net Sell 1 txn

Insider Lalwani Nikhil

Role PRESIDENT & CEO

Sold 5,400 shs ($383K)

Share of Position Sold 1.6%

Type	Security	Shares	Price	Value
Sale	Common Stock F1	5,400	$71.00	$383K

Holdings After Transaction: Common Stock — 339,089 shares (Direct)

Holdings Before and After: Common Stock, 344,489 to 339,089 shares (Direct)

Other Insiders: 3 other insiders reported open-market sales of this stock in the 30 days up to this filing.

Footnotes (1)

1. F1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 26, 2026.

Key Figures

Shares sold: 5,400 shares Sale price per share: $71.00 per share Total sale value: $383,400 +2 more

5 metrics

Shares sold 5,400 shares Common stock sale reported for September 15, 2026

Sale price per share $71.00 per share Price for the September 15, 2026 sale of ANI Pharmaceuticals common stock

Total sale value $383,400 Estimated proceeds from selling 5,400 shares at $71.00 per share

Shares held after transaction 339,089 shares Direct holdings of ANI Pharmaceuticals common stock by Nikhil Lalwani after the sale

Rule 10b5-1 plan adoption date May 26, 2026 Date the CEO’s trading plan governing the reported sale was adopted

Key Terms

Rule 10b5-1 trading plan, open market, private transaction

3 terms

Rule 10b5-1 trading plan regulatory

"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 26, 2026."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open market market

"Sale in open market or private transaction"

An open market is a system where buying and selling of goods, services, or financial assets happen freely without restrictions or special controls. For investors, it means they can trade assets easily and quickly, which helps determine fair prices based on supply and demand. This environment encourages transparency and competition, making it easier to buy or sell with confidence.

private transaction market

"Sale in open market or private transaction"

A private transaction is the sale or transfer of securities, assets, or ownership stakes carried out directly between a small number of parties rather than on a public exchange. For investors it matters because these deals are less visible and often less liquid than public trades, so pricing can be harder to verify, the investment can be harder to sell quickly, and buyers or sellers may gain strategic advantages not available in open markets — like negotiated terms similar to a private garage sale versus a crowded marketplace.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ANIP report for CEO Nikhil Lalwani?

ANI Pharmaceuticals reported that CEO Nikhil Lalwani sold 5,400 shares of common stock on September 15, 2026 at $71.00 per share, for total proceeds of about $383,400.

How many ANIP shares does the CEO hold after this Form 4 transaction?

After the reported sale, CEO Nikhil Lalwani directly holds 339,089 shares of ANI Pharmaceuticals common stock, as stated in the Form 4.

Was the ANIP CEO’s September 15, 2026 stock sale under a Rule 10b5-1 plan?

Yes. The filing states the sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Nikhil Lalwani on May 26, 2026.

What price did the ANIP CEO receive per share in the reported sale?

The Form 4 reports that Nikhil Lalwani sold ANI Pharmaceuticals common stock at $71.00 per share on September 15, 2026.

What is the total approximate value of the ANIP CEO’s reported stock sale?

Based on the Form 4 figures, selling 5,400 shares at $71.00 per share represents total proceeds of about $383,400 for the September 15, 2026 transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lalwani Nikhil

(Last) (First) (Middle)

C/O ANI PHARMACEUTICALS, INC.

104 CARNEGIE CENTER, SUITE 300

(Street)

PRINCETON NEW JERSEY 08540

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ANI PHARMACEUTICALS INC [ ANIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	PRESIDENT & CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/15/2026		S(1)		5,400	D	$71	339,089	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 26, 2026.

Remarks:

	/s/ Nikhil Lalwani, by attorney-in-fact Meredith W. Cook	09/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)